Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493687 | 0.89 | L3MBTL1 (0.51) | ALDH1A1L3MBTL3L3MBTL1KMT2ACNR1 | |
| SCHEMBL8473590 | 0.85 | ALDH1A1 (0.60) | TDP1ALDH1A1L3MBTL3L3MBTL1KMT2A | |
| SCHEMBL493765 | 0.83 | ALDH1A1 (0.63) | ALDH1A1L3MBTL3L3MBTL1KMT2AMEN1 | |
| SCHEMBL493703 | 0.83 | ALDH1A1 (0.46) | ALDH1A1L3MBTL3L3MBTL1KMT2AMEN1 | |
| SCHEMBL12499368 | 0.82 | ALDH1A1 (0.51) | TDP1ALDH1A1KMT2AMEN1CNR1 | |
| SCHEMBL4261834 | 0.81 | L3MBTL3 (0.55) | ALDH1A1L3MBTL3L3MBTL1KMT2AMEN1 | |
| SCHEMBL17888513 | 0.80 | KDM4E (0.59) | ALDH1A1KMT2AMEN1NPSR1KDM4E | |
| SCHEMBL494586 | 0.80 | ALDH1A1 (0.59) | ALDH1A1L3MBTL3L3MBTL1KMT2AMEN1 | |
| SCHEMBL4563012 | 0.80 | ALDH1A1 (0.43) | ALDH1A1L3MBTL3L3MBTL1KMT2AMEN1 | |
| SCHEMBL2430876 | 0.80 | L3MBTL3 (0.48) | ALDH1A1L3MBTL3L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | claimed |
| CN-101472910-A | 1- [(4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1 | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | CN | claimed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | claimed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | claimed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | claimed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| EP-2024354-B1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| CN-101472910-A | 1- [(4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1 | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | CN | disclosed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270398-A1 | New Compounds III | CYP11B2, CYP11B1, SDHA | TDP1 4219/4885ALDH1A1 561/4885L3MBTL3 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.